The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2.

Transforming growth factor-beta (TGF-beta) increases or decreases nuclear factor kappa B (NFkappaB) signaling in a context-dependent manner through mechanisms that remain to be defined. The type III transforming growth factor-beta receptor (TbetaRIII) is a TGF-beta superfamily co-receptor with emerging roles in both mediating and regulating TGF-beta superfamily signaling. We have previously reported a novel interaction of TbetaRIII with the scaffolding protein, beta-arrestin2, which results in TbetaRIII internalization and downregulation of TGF-beta signaling. beta-arrestin2 also scaffolds interacting receptors with the mitogen-activated protein kinase and NFkappaB-signaling pathways. Here, we demonstrate that TbetaRIII, through its interaction with beta-arrestin2, negatively regulates NFkappaB signaling in MCF10A breast epithelial and MDA-MB-231 breast cancer cells. Increasing TbetaRIII expression reduced NFkappaB-mediated transcriptional activation and IkappaBalpha degradation, whereas a TbetaRIII mutant unable to interact with beta-arrestin2, TbetaRIII-T841A, had no effect. In a reciprocal manner, short hairpin RNA-mediated silencing of either TbetaRIII expression or beta-arrestin2 expression increased NFkappaB-mediated transcriptional activation and IkappaBalpha degradation. Functionally, TbetaRIII-mediated repression of NFkappaB signaling is important for TbetaRIII-mediated inhibition of breast cancer cell migration. These studies define a mechanism through which TbetaRIII regulates NFkappaB signaling and expand the roles of this TGF-beta superfamily co-receptor in regulating epithelial cell homeostasis.

[1]  H. You,et al.  Endocytosis of the Type III Transforming Growth Factor-β (TGF-β) Receptor through the Clathrin-independent/Lipid Raft Pathway Regulates TGF-β Signaling and Receptor Down-regulation* , 2008, Journal of Biological Chemistry.

[2]  G. Blobe,et al.  Endoglin Promotes Transforming Growth Factor β-mediated Smad 1/5/8 Signaling and Inhibits Endothelial Cell Migration through Its Association with GIPC* , 2008, Journal of Biological Chemistry.

[3]  C. Arteaga,et al.  Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells. , 2008, Cancer research.

[4]  C. Wood,et al.  Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta. , 2008, Carcinogenesis.

[5]  Gerard C Blobe,et al.  Role of transforming growth factor-beta superfamily signaling pathways in human disease. , 2008, Biochimica et biophysica acta.

[6]  G. Blobe,et al.  Bone Morphogenetic Proteins Signal through the Transforming Growth Factor-β Type III Receptor* , 2008, Journal of Biological Chemistry.

[7]  W. Schiemann,et al.  Altered TAB1:I kappaB kinase interaction promotes transforming growth factor beta-mediated nuclear factor-kappaB activation during breast cancer progression. , 2008, Cancer research.

[8]  G. Blobe,et al.  TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. , 2008, Carcinogenesis.

[9]  G. Blobe,et al.  Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. , 2008, Carcinogenesis.

[10]  H. You,et al.  The type III TGF-beta receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation. , 2007, Carcinogenesis.

[11]  C. Arteaga,et al.  Modulation of NFκB Activity and E-cadherin by the Type III Transforming Growth Factor β Receptor Regulates Cell Growth and Motility* , 2007, Journal of Biological Chemistry.

[12]  S. Murphy,et al.  Loss of betaglycan expression in ovarian cancer: role in motility and invasion. , 2007, Cancer research.

[13]  Chien-Huang Lin,et al.  Transforming growth factor-beta1 stimulates heme oxygenase-1 expression via the PI3K/Akt and NF-kappaB pathways in human lung epithelial cells. , 2007, European journal of pharmacology.

[14]  Tao Lu,et al.  Dose-dependent cross-talk between the transforming growth factor-β and interleukin-1 signaling pathways , 2007, Proceedings of the National Academy of Sciences.

[15]  G. Blobe,et al.  The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. , 2007, Cancer research.

[16]  B. Moeller,et al.  The type III TGF-β receptor suppresses breast cancer progression , 2007 .

[17]  J. Marks,et al.  The type III TGF-beta receptor suppresses breast cancer progression. , 2007, The Journal of clinical investigation.

[18]  C. Arteaga,et al.  Modulation of NFkappaB activity and E-cadherin by the type III transforming growth factor beta receptor regulates cell growth and motility. , 2007, The Journal of biological chemistry.

[19]  Brian Bierie,et al.  Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer , 2006, Nature Reviews Cancer.

[20]  M. Karin.  Nuclear factor-κB in cancer development and progression , 2006, Nature.

[21]  Hui Wang,et al.  Novel roles of Akt and mTOR in suppressing TGF‐β/ALK5‐mediated Smad3 activation , 2006 .

[22]  M. Karin.  Nuclear factor-kappaB in cancer development and progression. , 2006, Nature.

[23]  Jiuhong Kang,et al.  β‐Arrestin2 functions as a phosphorylation‐regulated suppressor of UV‐induced NF‐κB activation , 2005 .

[24]  G. Blobe,et al.  Cell-surface co-receptors: emerging roles in signaling and human disease. , 2005, Trends in biochemical sciences.

[25]  C. Heldin,et al.  Non-Smad TGF-β signals , 2005, Journal of Cell Science.

[26]  D. Kögel,et al.  TGF-β1 activates two distinct type I receptors in neurons , 2005, The Journal of Cell Biology.

[27]  Gerard C Blobe,et al.  Role of transforming growth factor Beta in human cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Anita B. Roberts,et al.  Role of Rho/ROCK and p38 MAP Kinase Pathways in Transforming Growth Factor-β-mediated Smad-dependent Growth Inhibition of Human Breast Carcinoma Cells in Vivo* , 2004, Journal of Biological Chemistry.

[29]  Jiuhong Kang,et al.  Beta-arrestin2 functions as a phosphorylation-regulated suppressor of UV-induced NF-kappaB activation. , 2005, The EMBO journal.

[30]  C. Heldin,et al.  Non-Smad TGF-beta signals. , 2005, Journal of cell science.

[31]  F. Chen.  Arresting NF-κB by β-arrestin2 , 2004, Cell Death and Differentiation.

[32]  H. You,et al.  A pathway involving protein kinase Cδ up-regulates cytosolic phospholipase A2α in airway epithelium , 2004 .

[33]  Andreas Sommer,et al.  NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression , 2004 .

[34]  Ying E. Zhang,et al.  Smad-Binding Defective Mutant of Transforming Growth Factor β Type I Receptor Enhances Tumorigenesis but Suppresses Metastasis of Breast Cancer Cell Lines , 2004, Cancer Research.

[35]  R. Lefkowitz,et al.  β-Arrestin inhibits NF-κB activity by means of its interaction with the NF-κB inhibitor IκBα , 2004 .

[36]  Yue Sun,et al.  Identification of β-Arrestin2 as a G Protein-Coupled Receptor-Stimulated Regulator of NF-κB Pathways , 2004 .

[37]  Stephen W. Michnick,et al.  PKB/Akt modulates TGF-β signalling through a direct interaction with Smad3 , 2004, Nature Cell Biology.

[38]  T. Macdonald,et al.  A Failure of Transforming Growth Factor-β1 Negative Regulation Maintains Sustained NF-κB Activation in Gut Inflammation* , 2004, Journal of Biological Chemistry.

[39]  R. Lefkowitz,et al.  beta-Arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[40]  H. You,et al.  A pathway involving protein kinase Cdelta up-regulates cytosolic phospholipase A(2)alpha in airway epithelium. , 2004, Biochemical and Biophysical Research Communications - BBRC.

[41]  Yue Sun,et al.  Identification of beta-arrestin2 as a G protein-coupled receptor-stimulated regulator of NF-kappaB pathways. , 2004, Molecular cell.

[42]  H. Pehamberger,et al.  NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. , 2004, The Journal of clinical investigation.

[43]  Bruce A Luxon,et al.  Genomic profiling identifies alterations in TGFβ signaling through loss of TGFβ receptor expression in human renal cell carcinogenesis and progression , 2003, Oncogene.

[44]  Xiao-Fan Wang,et al.  ß-Arrestin 2 Mediates Endocytosis of Type III TGF-ß Receptor and Down-Regulation of Its Signaling , 2003, Science.

[45]  R. Weinberg,et al.  Heart and Liver Defects and Reduced Transforming Growth Factor β2 Sensitivity in Transforming Growth Factor β Type III Receptor-Deficient Embryos , 2003, Molecular and Cellular Biology.

[46]  W. Vale,et al.  Inhibin Is an Antagonist of Bone Morphogenetic Protein Signaling* , 2003, The Journal of Biological Chemistry.

[47]  S. Thorgeirsson,et al.  Transient activation of NF-κB through a TAK1/IKK kinase pathway by TGF-β1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation , 2003, Oncogene.

[48]  Xiao-Fan Wang,et al.  Beta-arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of its signaling. , 2003, Science.

[49]  W. Zong,et al.  Mechanisms of constitutive NF‐κB activation in human prostate cancer cells , 2002, The Prostate.

[50]  P. H. Anborgh,et al.  β-Arrestins regulate a Ral-GDS–Ral effector pathway that mediates cytoskeletal reorganization , 2002, Nature Cell Biology.

[51]  Ying E. Zhang,et al.  TGF‐β receptor‐activated p38 MAP kinase mediates Smad‐independent TGF‐β responses , 2002 .

[52]  R. Lefkowitz,et al.  Arresting developments in heptahelical receptor signaling and regulation. , 2002, Trends in cell biology.

[53]  R. Lefkowitz,et al.  The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. , 2002, Journal of cell science.

[54]  G. Stark,et al.  Distinct Roles of the IκB Kinase α and β Subunits in Liberating Nuclear Factor κB (NF-κB) from IκB and in Phosphorylating the p65 Subunit of NF-κB* , 2001, The Journal of Biological Chemistry.

[55]  G. Stark,et al.  Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B. , 2002, The Journal of biological chemistry.

[56]  Li J. Yu,et al.  TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. , 2002, The EMBO journal.

[57]  H. Lodish,et al.  A novel mechanism for regulating transforming growth factor beta (TGF-beta) signaling. Functional modulation of type III TGF-beta receptor expression through interaction with the PDZ domain protein, GIPC. , 2001, The Journal of biological chemistry.

[58]  Harvey F. Lodish,et al.  Functional Roles for the Cytoplasmic Domain of the Type III Transforming Growth Factor β Receptor in Regulating Transforming Growth Factor β Signaling* , 2001, The Journal of Biological Chemistry.

[59]  M. D. de Caestecker,et al.  Transcriptional Cross-talk between Smad, ERK1/2, and p38 Mitogen-activated Protein Kinase Pathways Regulates Transforming Growth Factor-β-induced Aggrecan Gene Expression in Chondrogenic ATDC5 Cells* , 2001, The Journal of Biological Chemistry.

[60]  H. Lodish,et al.  Functional roles for the cytoplasmic domain of the type III transforming growth factor beta receptor in regulating transforming growth factor beta signaling. , 2001, The Journal of biological chemistry.

[61]  H. Nakshatri,et al.  Repression of transforming-growth-factor-β-mediated transcription by nuclear factor κB , 2000 .

[62]  H. Lodish,et al.  Role of transforming growth factor beta in human disease. , 2000, The New England journal of medicine.

[63]  K. Lewis,et al.  Betaglycan binds inhibin and can mediate functional antagonism of activin signalling , 2000, Nature.

[64]  J. Massagué,et al.  TGFbeta signaling in growth control, cancer, and heritable disorders. , 2000, Cell.

[65]  H. Nakshatri,et al.  Repression of transforming-growth-factor-beta-mediated transcription by nuclear factor kappaB. , 2000, The Biochemical journal.

[66]  C. Heldin,et al.  Specificity, diversity, and regulation in TGF‐β superfamily signaling , 1999 .

[67]  Raymond B. Runyan,et al.  Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart. , 1999, Science.

[68]  Douglas B. Evans,et al.  The Nuclear Factor-κB RelA Transcription Factor Is Constitutively Activated in Human Pancreatic Adenocarcinoma Cells , 1999 .

[69]  C. Heldin,et al.  Specificity, diversity, and regulation in TGF-beta superfamily signaling. , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[70]  E. Friedman,et al.  Differential responsiveness to autocrine and exogenous transforming growth factor (TGF) beta1 in cells with nonfunctional TGF-beta receptor type III. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[71]  H. Lodish,et al.  Synergistic cooperation of TFE3 and smad proteins in TGF-beta-induced transcription of the plasminogen activator inhibitor-1 gene. , 1998, Genes & development.

[72]  A. E. Rogers,et al.  Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. , 1997, The Journal of clinical investigation.

[73]  M. Arsura,et al.  Nuclear factor-kappaB/Rel blocks transforming growth factor beta1-induced apoptosis of murine hepatocyte cell lines. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[74]  P. Hoodless,et al.  MADR2 Is a Substrate of the TGFβ Receptor and Its Phosphorylation Is Required for Nuclear Accumulation and Signaling , 1996, Cell.

[75]  J. Benovic,et al.  β-Arrestin acts as a clathrin adaptor in endocytosis of the β2-adrenergic receptor , 1996, Nature.

[76]  M. Arsura,et al.  TGFβ1 Inhibits NF-κB/Rel Activity Inducing Apoptosis of B Cells: Transcriptional Activation of IκBα , 1996 .

[77]  J. Benovic,et al.  Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. , 1996, Nature.

[78]  M. Arsura,et al.  TGF beta 1 inhibits NF-kappa B/Rel activity inducing apoptosis of B cells: transcriptional activation of I kappa B alpha. , 1996, Immunity.

[79]  J. Roth,et al.  Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma. , 1995, Oncogene.

[80]  Jeffrey L. Wrana,et al.  TGFβ signals through a heteromeric protein kinase receptor complex , 1992, Cell.

[81]  J. Massagué,et al.  TGF beta signals through a heteromeric protein kinase receptor complex. , 1992, Cell.

[82]  A. V. van Zonneveld,et al.  Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. , 1991, The Journal of biological chemistry.